Literature DB >> 1762305

Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance.

S Rekola1, A Bergstrand, H Bucht.   

Abstract

In 191 patients with mesangial IgA nephropathy, GFR was determined as clearance of 51Cr-EDTA. 86 (45%) of them had subnormal renal function 7.3 +/- 4.6 years after renal biopsy. The change in GFR was followed in 153 patients with repeated determinations of 51Cr-EDTA clearance. 50.3% of the patients had a loss of more than 1.1 ml/min/year, which we regard as pathological. The markers of progressive disease were: male sex, high output of urinary protein, severe histological lesions and presence of hypertension. Even patients lacking these markers had a significantly increased incidence of progressive disease. Of 93 patients, with initially normal GFR, 32% will have a subnormal GFR within five years and 25% will develop end-stage renal failure within 20 years. In 38 patients with six or more determinations of 51Cr-EDTA clearance, the predictive value of the first four determinations was calculated. Of 26 with a decrease of more than 1.1 ml/min/year, 13 (50%) developed subnormal GFR during follow-up, while 11 of 12 (91.7%) with a decrease of less than 1.1 ml/min/year (P less than 0.05) remained normal. This shows that repeated determinations of GFR with an accurate method will predict the final outcome early in the disease. We also confirmed that single or repeated determinations of clearance of creatinine are of little value in separating a normal GFR from a slightly decreased one, but more reliable in detecting a markedly reduced GFR.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1762305     DOI: 10.1038/ki.1991.313

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Antifibrotic effect of tamoxifen in a model of progressive renal disease.

Authors:  Humberto Dellê; José Roberto C Rocha; Rita C Cavaglieri; José Mauro Vieira; Denise M A C Malheiros; Irene L Noronha
Journal:  J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 10.121

2.  Efficacy and safety of artesunate for patients with IgA nephropathy: a study protocol for a multicenter, double-blind, randomized, placebo-controlled trial.

Authors:  Qi Chen; Zi Wang; Jicheng Lv; Lijun Liu; Hang Li; Weiwei Sun; Yanhong Huo; Yingbo Guo; Cun Shen; Shichao Li; Zhenjie Chen; Jingwei Zhou
Journal:  Trials       Date:  2022-05-25       Impact factor: 2.728

3.  The urine albumin-to-creatinine ratio is a reliable indicator for evaluating complications of chronic kidney disease and progression in IgA nephropathy in China.

Authors:  Lu Huan; Luo Yuezhong; Wang Chao; Tu HaiTao
Journal:  Clinics (Sao Paulo)       Date:  2016-05       Impact factor: 2.365

4.  Gender Differences in the Progression of Experimental Chronic Kidney Disease Induced by Chronic Nitric Oxide Inhibition.

Authors:  Camilla Fanelli; Humberto Dellê; Rita Cassia Cavaglieri; Wagner Vasques Dominguez; Irene L Noronha
Journal:  Biomed Res Int       Date:  2017-10-18       Impact factor: 3.411

5.  Comparison between C4d immunohistochemical staining and other clinical-histopathological findings in IgA nephropathy.

Authors:  Tala Pourlak; Seyyed Hamed Sharif Arani; Sima Abediazar; Hossein Samadi Kafil
Journal:  Biomedicine (Taipei)       Date:  2021-06-01

6.  Case series of idiopathic intracranial hypertension in three patients with immune-complex glomerulonephritis.

Authors:  Felix Fischbach; Anne Deborah Scholz-Hehn; Christian Gerloff; Monika Pötter-Nerger
Journal:  BMC Neurol       Date:  2021-07-13       Impact factor: 2.474

7.  Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology.

Authors:  Linghong Huang; Alessandra Scarpellini; Muriel Funck; Elisabetta A M Verderio; Timothy S Johnson
Journal:  Nephron Extra       Date:  2013-01-11

8.  Chapter 10: Immunoglobulin A nephropathy.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.